Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc (FHTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Foghorn Therapeutics Discontinues Development of FHD-286 for AML, Shifts Focus to Proprietary Pipeline and Collaborations Quiver Quantitative, Inc. - Mon Dec 16, 4:20PM CST

Foghorn Therapeutics halts FHD-286 development for AML, focusing on proprietary pipeline and Lilly collaboration; strong cash position until 2027.Quiver AI SummaryFoghorn Therapeutics announced the discontinuation...

FHTX : 5.14 (+3.21%)
Foghorn Therapeutics Stock Slides On Cancer Drug Development Halt, But Retail Remains Upbeat Stocktwits - Mon Dec 16, 1:30PM CST

The company stated that while clinical responses were observed, it decided to shift resources to its proprietary pipeline and collaborations with Eli Lilly.

FHTX : 5.14 (+3.21%)
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities GlobeNewswire - Mon Dec 16, 6:00AM CST

FHTX : 5.14 (+3.21%)
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences GlobeNewswire - Tue Nov 12, 6:54AM CST

FHTX : 5.14 (+3.21%)
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update GlobeNewswire - Mon Nov 4, 3:05PM CST

FHTX : 5.14 (+3.21%)
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors GlobeNewswire - Thu Oct 10, 6:00AM CDT

FHTX : 5.14 (+3.21%)
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase Newswire.ca - Tue Sep 24, 8:15AM CDT

/CNW/ -- USA News Group – Optimism is on the rise in fight against cancer, as researchers are making progress across the field of oncology. Helping to spur on...

ONCY : 0.8310 (-6.36%)
FHTX : 5.14 (+3.21%)
NRIX : 19.83 (-1.05%)
INCY : 68.84 (+2.65%)
ONC.TO : 1.19 (-9.16%)
REGN : 701.85 (-0.90%)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List PR Newswire - Wed Sep 27, 2023

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)

Barchart Exclusives

How To Profit From The Latest Corporate Spinoffs: A Guide For Investors In 2025 Barchart - 57 minutes ago
How to navigate corporate spinoffs. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot